CRISPR Therapeutics AG announced the appointment of Julianne Bruno as the new Chief Operating Officer effective May 23, 2024. Bruno, who has been with the company since April 2019, previously served as Senior Vice President and Head of Programs & Portfolio Management. Her promotion follows a successful tenure overseeing the hemoglobinopathy partnership program with Vertex Pharmaceuticals and the company's immuno-oncology trials. Bruno's new employment agreement includes an annual salary of $460,000, eligibility for the company's annual bonus program with a target bonus of 45% of her base salary, and a one-time grant of 20,000 restricted stock units. The agreement also outlines terms for termination and provides for a six-month notice period, with provisions for a 12-month notice period and immediate vesting of equity awards in the event of a termination following a Change in Control. The company filed the full text of the Employment Agreement with the SEC as Exhibit 10.1.

CRISPR Therapeutics AG announced the appointment of Julianne Bruno as the new Chief Operating Officer effective May 23, 2024. Bruno, who has been with the company since April 2019, previously served as Senior Vice President and Head of Programs & Portfolio Management. Her promotion follows a successful tenure overseeing the hemoglobinopathy partnership program with Vertex Pharmaceuticals and the company's immuno-oncology trials. Bruno's new employment agreement includes an annual salary of $460,000, eligibility for the company's annual bonus program with a target bonus of 45% of her base salary, and a one-time grant of 20,000 restricted stock units. The agreement also outlines terms for termination and provides for a six-month notice period, with provisions for a 12-month notice period and immediate vesting of equity awards in the event of a termination following a Change in Control. The company filed the full text of the Employment Agreement with the SEC as Exhibit 10.1.